Compare AstraZeneca plc (AZN) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Hilton Hotels Corporation Common Stock — how do they compare? AstraZeneca plc trades at $168.64 (market cap $253.13B), while Hilton Hotels Corporation Common Stock trades at $328.34 (market cap $74.18B). The key difference: AstraZeneca plc is far larger — about 3.4× Hilton Hotels Corporation Common Stock's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | HLT | |
|---|---|---|
Market Cap | $253.13B | $74.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $350.22 |
52-Week Low | $137.44 | $256.75 |
Enterprise Value | $279.37B | $86.68B |
Dividend Yield | 1.92% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Hilton Worldwide (HLT) trades at $322.45, down 3.88% amid bearish technical signals, though it maintains strong fundamentals with consistent earnings beats and revenue growth to $12.04B in 2025. Analyst consensus remains bullish with a $340.50 price target, supported by 55% buy ratings. Recent news highlights brand campaigns and renovations, while financials show robust cash flow but rising debt levels.
The stock offers upside to analyst targets but faces near-term technical pressure and leverage concerns. Investment appeal hinges on execution of growth initiatives and debt management, with risks including economic sensitivity and competitive pressures in the hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
